MR 1817
Alternative Names: MR1817; VRA-175Latest Information Update: 16 Jul 2016
At a glance
- Originator Mochida Pharmaceutical
- Class Analgesics
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (PO)
- 31 Jan 2011 Mochida Pharmaceutical completes a phase I trial in Healthy volunteers in the UK (NCT00960180)
- 31 Jul 2010 Phase-I clinical trials in Pain in USA (PO)